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Abstract  85 
The Amyloid Precursor Protein (APP) has been extensively studied as the precursor of the β-86 
amyloid peptide (Aβ) peptide, the major component of the senile plaques found in the brain of 87 
Alzheimer’s disease (AD) patients. However, the function of APP per se in neuronal physiology 88 
remains to be fully elucidated. APP is expressed at high levels in the brain. It resembles a cell 89 
adhesion molecule or a membrane receptor, suggesting that its function relies on cell-cell 90 
interaction and/or activation of intracellular signaling pathways. In this respect, the APP 91 
intracellular domain (AICD) was reported to act as a transcriptional regulator. Here, we used a 92 
transcriptome-based approach to identify the genes transcriptionally regulated by APP in the 93 
rodent embryonic cortex and upon maturation of primary cortical neurons. Surprisingly, the 94 
overall transcriptional changes were subtle, but a more detailed analysis pointed to genes 95 
clustered in neuronal-activity dependent pathways. In particular, we observed a decreased 96 
transcription of Neuronal PAS domain protein 4 (NPAS4) in APP-/- neurons. NPAS4 is an 97 
inducible transcription factor (ITF) regulated by neuronal depolarization. The down-regulation of 98 
NPAS4 co-occurs with an increased production of the inhibitory neurotransmitter GABA and a 99 
reduced expression of the GABAA receptors alpha1. CRISPR-Cas-mediated silencing of NPAS4 100 
in neurons led to similar observations. Patch-clamp investigation did not reveal any functional 101 
decrease of GABAA receptors activity, but LTP measurement supported an increased GABA 102 
component in synaptic transmission of APP-/- mice. Together, NPAS4 appears to be a 103 
downstream target involved in APP-dependent regulation of inhibitory synaptic transmission. 104 
  105 
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Significance Statement  106 
The Amyloid Precursor Protein (APP) is a key player in Alzheimer’s disease (AD) pathogenesis. 107 
We report the down-regulation of the activity-dependent transcription factor Neuronal PAS 108 
domain protein 4 (NPAS4) in APP-deficient neurons, along with an increase in GABAergic 109 
neuron markers and GABA release, but not in excitatory glutamatergic markers. We identified 110 
NPAS4 as an APP target gene by a transcriptome analysis of APP+/+ versus APP-/- primary 111 
cortical neurons at different stages of differentiation. The downregulation of NPAS4 observed in 112 
APP-/- neurons was confirmed by APP silencing with a CRISPR/Cas9 approach. CRISPR/Cas9-113 
silencing of NPAS4 mimicked APP deficiency and increased GABAergic markers. The activity-114 
dependent transcription factor NPAS4 is therefore a key downstream target in the synaptic 115 
functions regulated by APP. 116 
  117 
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Introduction  118 
The physiological functions of APP per se have been largely overlooked in comparison with its 119 
role of precursor of the Aβ peptide. Aβ deposition is a central event in AD, but alterations of APP 120 
physiological functions are likely to play a key role in the pathogenesis. 121 
APP belongs to the APP-like protein family (with APLP1 and APLP2, referred to as APLPs), 122 
expressed in most of the species. The APLP family results from several duplications and 123 
contraction events during evolution. The specific functions ascribed to each member are yet not 124 
clearly defined (for a review see Shariati and De Strooper, 2013). APP-/- mice show a subtle 125 
phenotype, with reduced body and brain weight, reduced locomotor activity, gliosis, mild axonal 126 
growth/white matter defects (Guo et al., 2012; Muller et al., 2012; Muller and Zheng, 2012). 127 
However, a large range of functions have been attributed to APP including neuronal proliferation, 128 
differentiation (Freude et al., 2011; Hu et al., 2013) and migration during embryogenesis (Young-129 
Pearse et al., 2007). APP promotes neurite outgrowth (Hoe et al., 2009b), synapse formation 130 
and activity (Priller et al., 2006; Santos et al., 2009; Lee et al., 2010; Pierrot et al., 2013; 131 
Klevanski et al., 2015; Zou et al., 2016) in the central nervous system (CNS) or at the 132 
neuromuscular junction (Stanga et al., 2016). APP modulates the excitatory neurotransmission 133 
by interacting with AMPA (Lee et al., 2010) or NMDA  receptors (Cousins et al., 2009; Hoe et al., 134 
2009a). APP deficiency reduces paired pulse depression (PPD) in mice (Seabrook et al., 1999) 135 
and affects the expression of GABA receptors (Fitzjohn et al., 2000; Chen et al., 2017). Its 136 
overexpression induces hyperexcitability due to failure in GABAergic neurotransmission (Born et 137 
al., 2014), and triggers the GABA excitatory/inhibitory shift occurring during neuronal maturation 138 
(Doshina et al., 2017). 139 
Tuning inhibitory/excitatory neurotransmission is instrumental in neuronal plasticity and memory 140 
formation. This process is regulated by a set of transcription factors known as inducible 141 
transcription factors or ITFs. ITFs belong to the Immediate Early Genes (IEGs) family, and are 142 
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sensitive to neuronal activity. They control the mechanisms that “reshape” synaptic inputs on 143 
neurons (West and Greenberg, 2011), and play a key role in neuronal plasticity and memory 144 
formation (Alberini, 2009; Loebrich and Nedivi, 2009; Leslie and Nedivi, 2011). Among them, 145 
NPAS4 is robustly expressed upon neuronal depolarization, and is involved in a transcriptional 146 
program that regulates neuronal firing responses to excitatory transmission by enhancing 147 
inhibition (Lin et al., 2008). Elevated activity of inhibitory neurons also induces NPAS4, 148 
promoting increased excitation onto the same neurons (Spiegel et al., 2014).  149 
The molecular mechanisms underlying APP functions are still elusive, but several studies 150 
reported that APP function is mediated by the transcriptional regulation of so-called APP target 151 
genes, which is operated by the APP intracellular domain (AICD). An increasing list of AICD 152 
candidate genes has emerged from various models (reviewed in Pardossi-Piquard and Checler, 153 
2012). On the other hand, APP was also reported to regulate gene transcription independently of 154 
AICD release (Hicks et al., 2013; Pierrot et al., 2013). It is thus so far quite impossible to clearly 155 
define (i) the precise identity of APP target genes in neurons (ii) the related molecular pathways 156 
underlying APP-dependent gene transcription (iii) how APP target genes relate to APP neuronal 157 
function. 158 
In this study, we first aimed at identifying genes that are transcriptionally regulated by APP in 159 
primary neurons. We performed a transcriptome analysis (APP+/+ vs. APP-/-) in primary cortical 160 
neurons at different stages of differentiation. Changes observed in global gene expression in the 161 
absence of APP were subtle. A more detailed pathway analysis indicated that expression of 162 
genes clustered in activity-dependent pathway, and among these the ITF NPAS4, were down-163 
regulated in the absence of APP after 7 days of culture. Strikingly, we observed that the amount 164 
of the inhibitory neurotransmitter GABA (γ-aminobutyric acid) was increased in APP-/- neurons. 165 
This was supported by an increased expression of the Glutamate Decarboxylase 65 (GAD65) in 166 
the same context. Glutamate levels were not altered in APP-/- neurons. These observations 167 
 8 
 
were reproduced upon acute silencing of APP by CRISPR-Cas9 editing. The knockdown of 168 
NPAS4 gave similar results. Neurophysiological investigations showed that excitatory 169 
postsynaptic potentials (EPSP) consecutive to a Theta-burst stimulation (TBS) decreased in 170 
APP-/- supporting the increase release GABA, and suggesting increased inhibitory synaptic 171 
inputs in APP-/- neurons. Altogether, our data provide new insight into APP-dependent neuronal 172 
activity, indicating that NPAS4 is an APP downstream target gene, tuning the GABA-dependent 173 
activity in neuronal networks. 174 
175 
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Materials and Methods 176 
Antibodies, chemicals and reagents 177 
All media and reagents used for cell cultures were purchased from Thermo Fisher Scientific 178 
(Waltham, USA); Fetal Bovine Serum (FBS) was purchased from Biowest (Nuaillé, France). 179 
Analytical grade solvents and salts were purchased from Sigma-Aldrich (St-Louis, USA). sAPPα 180 
(S9564) and DAPI (D9542) were from Sigma-Aldrich (St-Louis, USA), Triton-X100 from Merck 181 
(Darmstadt, Germany) and TriPure Isolation Reagent from Roche (Basel, Switzerland). 182 
Microarray analysis kits were from Affymetrix (Santa Clara, USA). All reagents for RNA 183 
processing or cDNA synthesis were from Bio-Rad (Hercules, USA), and primers were from 184 
Sigma-Aldrich (St Louis, USA). BCA Protein Assay kit was from Thermo Fisher Scientific 185 
(Waltham, USA). NuPAGE® reagents were from Invitrogen (Carlsbad, USA). PolyVinyliDene 186 
Fluoride (PVDF) and nitrocellulose membranes were from Merck Millipore (Billerica, USA) or 187 
Amersham™ (Little Chalfont, UK). Nonfat dry milk was from Merck (Darmstadt, Germany). 188 
Western Lighting® Plus-ECL reagents were from PerkinElmer (Waltham, USA) and Fluoprep 189 
mounting medium from bioMérieux (Marcy l’Etoile, France). Lentivirus were prepared with 190 
Acrodisc® 0,45μm filters (Pall, NYC, USA) and LentiX™ Concentrator reagent (Clontech, 191 
Mountain View, USA). 192 
The following antibodies were used: APP NT 22C11 (Cat. No. MAB348, Merck Millipore, 193 
Billerica, USA), anti-human APP W0-2 (Cat. No.MABN10, Merck Millipore, Billerica, USA), anti-194 
APP CT Y188 (Cat. No. ab32136 Abcam, Cambridge, UK), anti-APLP1 (Cat. No. 171615, 195 
Calbiochem EMD Biosciences – Merck, Darmstadt, Germany), anti-APLP2 (Cat. No. 171616, 196 
Calbiochem EMD Biosciences – Merck, Darmstadt, Germany), anti-GAPDH 14C10 (Cat. No. 197 
2118, Cell Signaling, Danvers, USA), anti-MAP2 (Cat. No. M4403, Sigma-Aldrich St Louis, 198 
USA), anti-GAD65 (D5G2, Cat. No. 5843 Cell Signaling, Danvers, USA), anti-mouse IgG, HRP 199 
Whole antibody anti-rabbit IgG HRP (Cat. No. NA931-1ML, Amersham, Little Chalfont, UK), 200 
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whole goat anti-mouse antibody (Cat. No. NA934-1ML, Amersham, Little Chalfont, UK) Alexa 201 
Fluor®-488, goat anti-mouse; Alexa Fluor®-568, goat anti-rabbit; Alexa Fluor®-647 and DAPI 202 
were purchased from ThermoFisher Scientific (Waltham, USA). Glutamate assay kit was from 203 
Abcam (Cambridge, UK) and γ-aminobutyric acid (GABA) ELISA from Cloud-Clone Corporation. 204 
70 μm Falcon™ Cell Stainers were from ThermoFisher Scientific (Waltham, USA). 205 
Animal models 206 
All animal procedures were performed in accordance with the regulations and policies of the 207 
University animal care committee. APP+/+ and APP-/- mice were obtained from the Jackson 208 
Laboratory (Bar Harbor, USA) as C57Bl6/J and backcrossed for > 6 generations in CD1 genetic 209 
background. Animals were housed on a 12 h light/dark cycle in standard animal care facility with 210 
access to food and water ad libitum. Heterozygous animals (APP+/-) were bred and crossed to 211 
obtain embryos of either sex from the three different genotypes (APP+/+, APP+/- and APP-/-) in 212 
the same litter.  213 
Primary culture and treatments 214 
Primary cultures of cortical neurons were prepared from E18 mouse embryos. Cortices were 215 
dissected and dissociated in HBSS without calcium and magnesium and the mixture was 216 
centrifuged on FBS for 10 min at 1,000 x g to pellet cells. Cells were plated at 200,000 cells/cm² 217 
in culture dishes pre-treated with 10 μg/ml of poly-L-lysine in phosphate buffered saline (PBS) 218 
and cultured (37°C, 5% CO2 and humidified atmosphere). Cells were cultured for 3 to 14 days in 219 
vitro in Neurobasal® medium enriched with 2% v/v B-27® supplement medium and 1 mM L-220 
glutamine. Half of the medium was renewed every 2-3 days. Treatments with 20 nM of soluble 221 
APPα (sAPPα) were performed for 16 h after 6 days of culture (DIV6).  222 
For primary cultures of astrocytes, cortices from pups were collected at postnatal day 2 and 223 
mechanically dissociated. Astrocytes were isolated using a 30% Percoll gradient and seeded 224 
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into gelatin-coated tissue culture flasks. Cells were left to proliferate for 14 days at 37°C - 5% 225 
CO2 in DMEM-glutaMAX medium supplemented with 10% FBS, 50 mg/ml penicillin–226 
streptomycin and 50 mg/ml fungizone. Medium was renewed after 7 days, cells were passaged 227 
after 14 days and further cultured in DMEM-glutaMAX with 10% FBS. Two days after passage, 228 
FBS was reduced to 3% and medium was supplemented with the growth factor cocktail G5. All 229 
experiments/treatments were performed 7 days after, referred to as DIV7 for astrocytes. For 230 
NPAS4-induction analysis, neurons and astrocytes at DIV7 were depolarized with 50 mM KCl for 231 
2-4h.  232 
RNA extraction, transcriptome analysis and qRT-PCR 233 
Total RNA was extracted by TriPure Isolation Reagent according to the manufacturer’s protocol. 234 
RNA samples were suspended in DEPC-treated water and RNA concentration was measured 235 
(OD 260 nm) on BioSpec-nano spectrophotometer (Shimadzu Biotech). For microarray analysis, 236 
RNA quality was monitored by capillary electrophoresis using the Agilent 2100 Bioanalyzer 237 
instrument with the Agilent RNA 6000 Nano Kit (Agilent, Santa Clara, USA). 250 ng of total RNA 238 
per sample was amplified and labeled using GeneChip®WT PLUS Reagent kit (Affymetrix, 239 
Santa Clara, USA) before hybridization over night at 45°C on GeneChip®Mouse Transcriptome 240 
1.0 Array. The chip was washed on the GeneChip® Fluidics Station 450 followed by scanning 241 
on a GeneChip® Scanner on Affymetrix microarray platform. For quantitative PCR, RNA 242 
samples were reversed transcribed using iScript cDNA Synthesis Kit and real time PCR was 243 
performed in an iCycler MyIQ2 multicolor-Real-Time PCR detection system using iQ SYBR 244 
Green supermix kit (Bio-Rad, Hercules, USA). A standard curve was established for relative 245 
quantification with a fourfold dilution series (from 100 to 0.0097 ng) of a cDNA template mix. 246 
Relative quantification was calculated by the 2ΔΔCT method (Gapdh as housekeeping control) 247 
and then normalized (percentage or fold) to the control condition (Ct). Primer used 248 
(forward/reverse) are : 249 
 12 
 
Gapdh 5’-ACCCAGAAGACTGTGGATGG-3’ / 5’- ACACATTGGGGGTAGGAACA-3’ 250 
Npas4 5’-GCTATACTCAGAAGGTCCAGAAGGC-3’ / 5’-TCAGAGAATGAGGGTAGCACAGC-3’ 251 
Egr1 5’-TCCTCTCCATCACATGCCTG-3’ / 5’-CACTCTGACACATGCTCCAG-3’ 252 
Egr3 5’-GACTCGGTAGCCCATTACAATC-3’ / 5’-ACTTTCCCAAGTAGGTCACGG-3’ 253 
Western blotting 254 
Cells were solubilized and sonicated in lysis buffer (20% Glycerol, 4% SDS, 125 mM Tris-HCl 255 
pH 6.8) containing a cocktail of proteases and phosphatases inhibitors (Roche, Basel, 256 
Switzerland). When performed on tissue extracts, mice were euthanized (Ketamine/Xylazine 257 
injection) and brains were dissected after perfusion with ice cold sterile PBS. Cortices and 258 
hippocampi were isolated and quickly frozen in liquid nitrogen. Tissues were crushed using 259 
mortar pestle method. For brain protein extraction, samples were homogenized in RIPA buffer 260 
(1% (w/v) NP40, 0.5% (w/v) deoxycholic acid, 0.1% (w/v) SDS, 150 mM NaCl, 1 mM EDTA, 50 261 
mM Tris, pH 7.4) containing proteases and phosphatases inhibitors cocktail. The samples were 262 
clarified by centrifugation at 20,000 x g. Protein concentrations were determined with a BCA kit. 263 
Samples were prepared with NuPAGE LDS sample buffer (4x) and 50 mM DTT and then heated 264 
for 10 min at 70°C. 10 to 40 μg of proteins or 22 μl of culture medium were loaded per well for 265 
migration followed by transfer onto PVDF or nitrocellulose membranes. For APP C-terminal 266 
fragments, proteins were transferred on nitrocellulose (0.1 μm). Membranes were blocked in 267 
nonfat dry milk (5% in PBS, 0.05% Tween-20) and immunoblotted with anti-APP NT (22C11, 268 
1/500), anti-APP CT (Y188, 1/500), anti-APLP1 (1/1000), anti-APLP2 (1/1000) and anti-GAPDH 269 
(1/25000). Blots were revealed using ECL and signal quantification was performed using 270 
GelQuant.NET software (BiochemLabSolutions.com). 271 
ImmunoCytoFluorescence (ICF) 272 
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Neurons grown at 100,000 cells/cm² per well on poly-L-lysine coated coverslips were fixed for 15 273 
min in PBS/4% paraformaldehyde and washed twice in PBS for 5 min. Permeabilization and 274 
blocking steps were done in PBS/5% skimmed milk/0.3% Triton-X100. Antibodies were 275 
incubated in PBS/5% skimmed milk/0.1% Triton-X100 (M1TPBS). Primary antibodies dilutions 276 
used were: mouse anti-MAP2 (1/1000), rabbit anti-APP (Y188, 1/100) and rabbit anti-GAD65 277 
(D5G2, 1/100). Secondary antibodies dilutions used were: goat anti-mouse Alexa Fluor®-488 278 
(1/500), goat anti-mouse Alexa Fluor®-568 (1/500) and goat anti-rabbit Alexa Fluor®-647 279 
(1/500). Images were acquired on Evos FL Auto microscope (Invitrogen) with GFP (Alexa 280 
Fluor®-488 or native GFP), TxRed (Alexa Fluor®-568) and CY5 (Alexa Fluor®-647) EVOS LED 281 
light cubes and analyzed with ImageJ software. For the quantification of signal area, 10X or 20X 282 
magnification images were identically thresholded for APP+/+ and APP-/-, or Ct and CRISPR-283 
NPAS4. The area of thresholded images was measured and normalized to the number of cells 284 
counted by DAPI staining. For the quantification of the APP expression intensity, image 285 
acquisition was performed using 40x objective coverslip-corrected (ThermoFischer Scientific, 286 
AMEP4699) in GFP, CY5 (APP) and DAPI channels. A total of 12, 19 and 19 images were 287 
acquired and processed to obtain 33, 46 and 51 neurons in the analysis (Figure 3B) for CRISPR 288 
control (Ct), Oligo2 and Oligo17 respectively. GFP channel images were first 8-bit transformed 289 
and thresholded to highlight only GFP staining. A region of interest (ROI) was delimited around 290 
GFP+ neurons in the GFP channel (green) using “wand tool” in imageJ software and transposed 291 
to CY5 (APP) channel (blue). ROI mean intensity is measured with the “Analyze” tool of ImageJ 292 
software.  293 
AICD and CRISPR/Cas9 lentiviral constructions, production and viral transduction  294 
Lentiviruses were used to express AICD in neurons. AICD50 tagged at the c-terminal part with 295 
hemagglutinin (HA) was cloned into pLenti CMV/TO Puro lentiviral vector (Addgene ref #17482). 296 
pLenti CMV/TO Puro empty served as a control (Ct). A lentiviral vector-based approach was 297 
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also used to deliver the CRISPR-Cas9 system. sgRNAs “Oligo2” and “Oligo17” were designed 298 
using on/off-target score algorithm to target the APP mouse gene (Gene ID: 11820), and sgRNA 299 
“CRISPR-NPAS4” to target the NPAS4 mouse gene (Gene ID: 225872). sgRNAs were cloned in 300 
a lentiviral vector delivering sgRNA, SpCas9 and coexpressing eGFP (Addgene #57818) 301 
according to author instructions (Heckl et al., 2014). The negative Ct used was the lentiviral 302 
construct without sgRNA but expressing SpCas9 and eGFP. sgRNA used are 303 
(sequence/PAM/specificity score): 304 
APP Oligo2 5’-GTGGAAGATCCGCCGCGCCC-3’ / TGG / 95 305 
APP Oligo17 5’-GTACCCACTGATGGCAACGC-3’ / CGG / 92 306 
Npas4  5’-GACCCTTGCGAGTGTAGATGC-3 / AGG / 83 307 
All lentiviral vectors were validated by sequencing (Beckman Coulter Genomics, UK) prior to 308 
production and purification using the Plasmid Midi kit (Qiagen, Hilden, Germany). Production 309 
was carried out by transfecting HEK293-T cells in 10 cm dishes (2x106 cells/dish) with lentiviral 310 
CRISPR-Cas9 vectors, pCMV-dR8.2 (Addgene#12263) and pMD2.G (Addgene#12259). After 311 
48 h, the supernatant was filtered and incubated with 1/3 (v/v) of LentiX™ Concentrator for 90 312 
min on ice. The collected supernatant was centrifuged at 1,500 x g for 45 min at 4°C, the pellet 313 
was resuspended in 20 μl per dish of Neurobasal® Medium and stored at -80°C until use.  314 
Neurons were infected with CRISPR-Cas9 lentiviruses 1 day after plating (DIV1). Typically, 20 μl 315 
of concentrated virus were used to infect 800,000 cells per well in a 12-well culture dish. The 316 
medium was completely changed after 24 hours, and a half-media change was performed every 317 
2-3 days thereafter. The neurons were harvested at DIV7 or as indicated. 318 
Toxicity assay 319 
Cell viability upon lentiviral infection was measured by lactate dehydrogenase (LDH) release in 320 
the culture medium using Cytotoxicity Detection kit (Sigma-Aldrich, St-Louis,USA), according to 321 
the manufacturer's instructions. Relative absorbance was measured at 490 nm using a VICTOR 322 
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Multilabel Plate Reader (PerkinElmer, Richmond, USA). Background LDH release was 323 
determined in non-infected control cultures. 324 
Flow cytometry and cell sorting 325 
At DIV7, infected neurons were briefly rinsed with PBS and trypsinized for 2 min. Neurons were 326 
mechanically dissociated and filtered through 70 μm Falcon™ Cell Strainers in 50 ml tube 327 
containing FBS. Cells were pelleted by centrifugation at 1,000 x g for 5 min and resuspended in 328 
PBS/1% FBS/1mM EDTA. TO-PRO™-3 Iodide (Thermo Fisher Scientific, Waltham, USA) was 329 
used to stain dead cells and exclude them for the sorting. Cells were sorted using a BD 330 
FACSAria™III cell sorter (BD Biosciences, San Jose, USA). The sort parameters used were the 331 
following: nozzle 100 μm, sheath pressure 20 psi, drop frequency 30 kHz and sort precision 16-332 
32-0. Sample and collection tubes were maintained at 4°C throughout the procedure. GFP-333 
negative and positive cells were harvested in PBS/1% FBS/1 mM EDTA, centrifuged at 1,2000 x 334 
g for 2 min and homogenized in TriPure Isolation Reagent for RNA extraction. 335 
Glutamate and GABA measurements 336 
Neurons were grown at 200,000 cells/cm² in 12 well culture dish. Glutamate and γ-aminobutyric 337 
acid (GABA) were measured in cells lysates and culture media at DIV7. Media were harvested, 338 
centrifuged to pellet and remove cellular debris, treated with a cocktail of proteases inhibitors 339 
and frozen at -20°C until use. Cells were scrapped in ice cold PBS, pelleted by centrifugation 340 
(12,000 x g for 3 min at 4°C), quickly frozen in liquid nitrogen and kept at -80°C until use. 341 
Glutamate and GABA assays were performed according to the manufacturer’s protocol (Abcam, 342 
Cambridge, UK). For both, cells were lysed by 5 cycles of thawing and freezing in PBS and 343 
centrifuged at 12,000 x g for 10 min at 4°C. Supernatants were used for the quantification and 344 
normalized on protein content. Media were directly used for quantification. 345 
Calcium imaging 346 
 16 
 
Changes in intracellular [Ca2+] were measured in single neurons using the calcium sensitive 347 
fluorescent dye Fura2 (Molecular Probes, Cambridge, UK). Neurons were grown on poly-L-348 
lysine-coated 15 mm diameter coverslips and were loaded with 2 μM Fura2-acetoxymethyl ester 349 
(Fura-2AM) for 40 min in a Krebs buffer (10 mM HEPES, 135 mM NaCl, 6 mM KCl, 2 mM 350 
CaCl2, 1.2 mM MgCl2,10 mM glucose, pH 7.4) at room temperature. Coverslips were rinsed 351 
once and then mounted on a heated (37°C) and perfused microscope chamber (Warner 352 
Instrument Corporation). While continuously perfused with heated Krebs buffer, Fura2-loaded 353 
neurons were excited successively at 340 and 380 nm (excitation light was obtained from a 354 
xenon lamp coupled to a monochromator) for 2x100 ms. Emitted fluorescence was monitored at 355 
510 nm using a charged coupled device sensor camera coupled to an inverted Olympus IX70 356 
microscope (TILL photonics). Fluorescence intensities from each single neuron was recorded 357 
separately, corrected for the background and combined (fluorescence ratio F340/F380) using 358 
the software TILLvisION version 3.3. Calcium signals were measured upon application 359 
(perfusion) of 30 μM glutamate (Glut) in Krebs buffer. A total of 70–80 cells were analyzed in 360 
each experiment (coverslips) and non-neuronal cells were excluded from analysis as previously 361 
described by Pickering and coworkers (Pickering et al., 2008). Changes in intracellular [Ca2+] 362 
were calculated from fluorescence emission intensity ratios (F340/F380). These changes were 363 
expressed as normalized fluorescence where every measurement of F340/F380 was divided by 364 
the basal fluorescence value corresponding to the mean of signals measured during a period of 365 
25 s in basal condition (prior to the glutamate stimulation). To estimate the amplitude of the 366 
response to glutamate, the area under curve (AUC) was calculated using GraphPad Prism 367 
(GraphPad Software, San Diego, USA).  368 
Field potential recordings 369 
3 months old mouse brain slices were prepared as described in (Lepannetier et al., 2018). 370 
Excitatory postsynaptic potentials (EPSP) were evoked through a bipolar stimulating electrode 371 
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placed in the Schaffer collaterals (SC) and recorded by the AxoClamp 2B (Axon Instruments, 372 
USA) amplifier through a glass electrode placed in the CA1 region (stratum radiatum). Stimuli 373 
consisted of 100 μs pulses of constant currents with intensity adjusted to produce 35% of the 374 
maximum response every min. Responses were digitized by Digidata1322A (Axon Instruments, 375 
USA) and recorded to a computer using WinLTP software (Anderson and Collingridge, 2007). 376 
Long-term potentiation was induced by applying a theta-burst stimulation (TBS) consisting in 377 
four trains of 5 pulses (100 Hz) separated by a 200 ms interval. Slopes of field excitatory 378 
postsynaptic potentials (fEPSP) responses were expressed normalized to the pre-treatment 379 
baseline, defined as 100%.  380 
Electrophysiology of cultured neurons 381 
Patch-clamp recordings of primary neurons at DIV7 were carried out at room temperature, using 382 
an EPC-9 amplifier controlled by PatchMaster software (HEKA Elektronik, Lambrecht, 383 
Germany). GABA was applied by pressure ejection using a Picospritzer. The patch pipettes 384 
were pulled with a resistance of 4–7 MΩ using a DMZ-Universal Puller (Zeitz Instruments, 385 
Munich, Germany). Series resistances were compensated (75–90%) and periodically monitored. 386 
The following extracellular solution was used (in mM): 140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 387 
glucose, and 10 HEPES, pH 7.4. The pipette solution had the following composition (in mM): 388 
140 CsCl, 10 EGTA, 0.3 Mg2ATP, 0.3 CaCl2, and 10 HEPES, pH 7.25. To prevent network 389 
activity, the experiments were performed in the presence of 1 μM tetrodotoxin (TTX), 10 μM 6-390 
cyano-7-nitroquinoxaline-2,3-dione disodium (CNQX) and 20 μM D-(-)-2-Amino-5-391 
phosphonopentanoic acid (D-AP5) and 100 nM CGP55845.  392 
Statistical analysis 393 
Microarray analysis: Raw data were analyzed using Bioconductor (R environment). Robust 394 
Multiarray Average (RMA) was used for background correction, normalization, probe level 395 
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intensity calculation and probe set summarization. Gene expression values were compared 396 
between APP+/+ and APP-/- neurons at different stage of development DIV3, DIV7 and E18 397 
using the R-Limma (Linear Models for MicroArray Data) package. Benjamini-Hochberg 398 
procedure was used for multiple testing corrections. Only transcripts with an Entrez ID were kept 399 
among the raw data in order to facilitate the analysis. Gene set enrichment analysis was 400 
performed on differentially expressed genes sets after the ROAST (Rotation gene set tests for 401 
complex microarray experiments) (Wu et al., 2010) procedure to identify KEGG pathways 402 
modified in absence of APP for all conditions (E18, DIV3 and DIV7). The data obtained have 403 
been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible 404 
through GEO Series. Otherwise, statistical analyses were performed using GraphPad Prism 405 
(GraphPad Software, San Diego, USA). Gaussian distribution was assessed by Kolmogorov-406 
Smirnov test (GraphPad Prism). Parametric test was applied if the data followed normal 407 
distribution. Otherwise non-parametric tests were used. When two groups were compared, 408 
parametric Student’s t-test or non-parametric Mann-Whitney test were used. When more than 409 
two groups were compared, parametric ANOVA with indicated post hoc tests or non-parametric 410 
Kruskall-Wallis were used. Significance is indicated as ns = non-significant; * p < 0.05; ** p < 411 
0.01; *** p < 0.001. The number of samples per condition in one experiment (n) and the number 412 
of biological replicates (N) are indicated in figure legends. 413 
 414 
415 
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Results 416 
APP-dependent expression of NPAS4 in differentiated primary neuron cultures 417 
Transcriptome analysis were performed on primary neurons and embryonic cortex according to 418 
the workflow described in Extended Data Fig. 1-1A. Neurons from embryonic cortex (E18) were 419 
cultured for 3 or 7 days in vitro (DIV3 or DIV7) and up to DIV14 when necessary. 420 
Characterization of APP protein family expression indicated an increase in APP, APLP1 and 421 
APLP2 upon differentiation with a peak of expression at DIV7-8 (Extended Data Fig. 1-1B-C), 422 
supporting an important role of APP protein family in neuronal maturation. APLP1 and APLP2 423 
levels were similar in APP-/- neurons and APP+/+ at any time point of differentiation (Extended 424 
Data Fig. 1-1D). Thus, the results obtained here in APP-/- neurons are related to the loss of APP 425 
and not to indirect effects resulting from up- or down-regulation of APLP1 or APLP2 in the 426 
absence of APP. 427 
Previous studies indicated that APP-dependent gene transcription involves the release of its 428 
intracellular domain or AICD. AICD is detectable in the nucleus of primary neurons at DIV6-7 429 
(Kimberly et al., 2005), suggesting that AICD-dependent gene transcription should be temporally 430 
restricted. We monitored AICD production at DIV7 in APP+/+, APP+/- and APP-/- cultures 431 
(Extended Data Fig. 1-1E). AICD was only readily detectable in APP+/+ neurons at a high 432 
exposure time, confirming (i) that it is a transient peptide (Huysseune et al., 2007) with a 433 
restricted temporally expression pattern in primary neurons and (ii) that APP-dependent 434 
transcriptional regulation may occur at a defined time-period (around DIV7). We thus performed 435 
microarray experiments at several differentiation stages (summarized in Extended Data Fig. 1-436 
1A) to track genome-wide expression changes in APP +/+ and APP-/- primary cortical neurons 437 
at DIV3 (immature neuronal network, no AICD), DIV7 (neuronal network with detectable AICD) 438 
and in E18 cortical tissue (embryonic tissue). We used Affymetrix GeneChip®Mouse 439 
Transcriptome 1.0 Array and performed data analysis with the R-Limma (Linear Models for 440 
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MicroArray Data) package (Ritchie et al., 2015). The chips used allowed profiling of the 441 
expression of coding and non-coding genes (lncRNA, miRNA, pseudogene…) as well as 442 
alternative splicing events. Transcriptome analysis was performed in triplicate (N=3 independent 443 
cultures) for each condition (E18, DIV3, and DIV7). We focused on differentially expressed 444 
coding genes, although data were also collected for non-coding RNAs. Strikingly, the overall 445 
changes observed (fold changes) were moderate in all conditions (E18, DIV3 and DIV7). Few 446 
coding transcripts appear to be differentially expressed when the specific fold change (linear) is 447 
set at 1.25, 1.5 or 2 (Fig. 1A). The Benjamini-Hochberg multiple correction test did not reveal 448 
any robust differential gene expression (adjusted p-value <0.05) excepted for APP (positive 449 
control). To note, we did not measure significant change in the expression of genes previously 450 
identified as AICD target genes (Pardossi-Piquard and Checler, 2012). Gene enrichment 451 
analysis was further performed using the ROAST (Rotation gene set test for complex microarray 452 
experiment) procedure to identify a molecular interaction/reaction networks diagram known as 453 
the KEGG pathway (Kanehisa and Goto, 2000) altered in the absence of APP. The first five 454 
pathways (in terms of significance), the number of genes modified as well as their direction are 455 
shown in Fig. 1B. For instance, ECM (extracellular matrix)-receptor interaction and Long-term 456 
potentiation pathways appeared to be modulated in absence of APP at DIV7. APP shares the 457 
structure of transmembrane receptors and cell adhesion proteins that activate Cell-ECM 458 
pathways. Long term potentiation (LTP) is a major mechanism in memory formation and 459 
learning. Both of these pathways have been associated to APP function (Caceres and Brandan, 460 
1997; Seabrook et al., 1999; Puzzo et al., 2011). We kept this pathways analysis to further 461 
investigate the regulation of candidate genes relevant to APP functions. In a set of arrays from a 462 
primary neuron at DIV7 (APP+/+ vs APP-/-), we noticed a down-regulation of Inducible 463 
Transcription Factors (ITFs) or Immediate Early Genes (IEGs) in APP-/- neurons (Fig. 1C). 464 
Among them, the activity-dependent transcription factor NPAS4 (Neuronal PAS domain protein 465 
4). NPAS4 is a neuron-specific ITF, known to be regulated by neuronal depolarization. We 466 
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confirmed by qPCR that the NPAS4 mRNA level was decreased at DIV7 in APP-/- neurons, but 467 
neither at DIV3 nor in the cortex at E18 (Fig. 1D). To note, the expression of other IEGs (Egr1 468 
and Egr3) previously reported to be APP downstream targets (Hendrickx et al., 2013;Hendrickx 469 
et al., 2014) was not altered in our experiments (See Extended Data Fig. 1-2). 470 
Control of NPAS4 expression by APP  471 
Since AICD - produced at DIV7 – is reported to mediate APP nuclear signaling (Belyaev et al., 472 
2010), we analyzed its involvement in NPAS4 expression. We transduced primary neurons with 473 
a lentiviral vector expressing the 50 C-terminal amino acids of APP (AICD) fused at the C-474 
terminus to the hemagglutinin tag (HA). AICD-HA is detectable in infected cells (Fig. 2A) and 475 
AICD expression in APP-/- neurons significantly increased NPAS4 mRNA levels (Fig. 2B), 476 
indicating that AICD is involved in the transcriptional regulation of NPAS4. As some of the APP 477 
functions were found to rely on its extracellular soluble fragment (sAPPα), we tested whether the 478 
sAPPα can regulate NPAS4 expression per se. Treatment of neuronal cultures with 20 nM of 479 
human sAPPα (Fig. 2C) significantly increased NPAS4 mRNA levels in APP+/+ neurons, but not 480 
in APP-/- neurons (Fig. 2D). Together, these data indicate that (i) AICD is likely to be involved in 481 
APP-dependent NPAS4 transcription (ii) soluble APP (sAPPα) triggers NPAS4 expression, but 482 
only in a context where endogenous APP is expressed. Importantly, glial cells (about ~16% of 483 
total cells in primary cultures) could indirectly contribute to these observations. We found that the 484 
absence of APP did not change the astrocytic pattern of primary cultures, and that astrocytes did 485 
not readily express NPAS4 in contrast to neuron (Extended Data Fig. 2-1). Moreover, NPAS4 is 486 
strongly induced as expected by depolarization only in neurons (Sun and Lin, 2016). Together, 487 
this indicated that NPAS4 is a downstream transcriptional target that could be involved in APP 488 
neuronal functions. 489 
The mild APP-dependent transcriptional regulations we observed are in line with the mild 490 
phenotype of APP knockout mice (Muller et al., 1994; Zheng et al., 1995). Still, APP-dependent 491 
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gene regulations that occur in the close-up could be hidden in the long term by functional 492 
redundancies with other members of the APP family (Shariati and De Strooper, 2013). In 493 
agreement, APP-/- phenotype is better unraveled by acute down-regulation of APP in the brain 494 
(Senechal et al., 2007). We performed a knockdown of APP expression in neurons with a 495 
lentiviral-based CRISPR-Cas9 genome editing approach (Jinek et al., 2012) to test the 496 
consequence of acute APP downregulation on NPAS4 expression. Nearly ~50% of the cells 497 
were infected and no lentiviral toxicity was measured under our conditions (Extended Data Fig. 498 
3-1). Only neuronal cells were infected, reflecting the tropism of the viral particles for neurons. 499 
APP expression was analyzed by ICF (Fig. 3A). Measurement of the intensity of APP signal in 500 
infected (GFP-positive) neurons (Fig. 3B) indicated a strong decrease in APP expression (40 to 501 
50%) in neurons infected with CRISPR-Cas9 viruses targeting APP exon1 and exon 2 (Oligo2 502 
and 17 sgRNA, respectively). This was confirmed by Western blotting (Fig. 3C). Importantly, 503 
expression of APLP1 and APLP2 was not altered in neurons infected under the same conditions, 504 
indicating that off target editing of APP did not occur in our experimental setup. To measure the 505 
expression of NPAS4 selectively in GFP-positive (knockdown) neurons, we sorted GFP positive 506 
neurons by flow cytometry (Fig. 3D). TO-PRO™-3 staining was used as a viability marker to 507 
exclude dead cells from the analysis. The sorting parameters were set by using non-infected 508 
neurons (GFP negative) and neurons expressing GFP (GFP positive) as standards. NPAS4 509 
mRNA was readily decreased in neurons infected with Oligo2- and 17-expressing lentiviruses 510 
(GFP positive). Thus, acute APP knockdown resulted in decreased NPAS4 mRNA levels, 511 
confirming the APP-dependent NPAS4 transcriptional regulation observed in APP-/- neurons. 512 
APP deficiency increases markers associated to GABAergic transmission 513 
NPAS4 is an ITF induced by neuronal activity. The down-regulation of NPAS4 expression 514 
observed in the absence of APP could reflect an impairment in the establishment of a functional 515 
network, leading to defects in basal neuronal activity. APP was reported to modulate neurite 516 
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outgrowth and synapse formation (Priller et al., 2006; Young-Pearse et al., 2007; Tyan et al., 517 
2012; Billnitzer et al., 2013). We analyzed neuronal arborization by measuring the area of the 518 
neuron-specific microtubule associated protein2 (MAP2) signal per cell from DIV1 to DIV7 (Fig. 519 
4). Neurite extension observed in APP+/+ and APP-/- neurons was not significantly different at 520 
DIV1 and DIV3. Strikingly, the absence of APP significantly increased MAP2 signal at DIV7, 521 
indicating the importance of APP for in neurite arborization and formation of a functional 522 
network. This observation reinforced the possible involvement of NPAS4 in APP physiological 523 
function. NPAS4 activity scales the neuronal network by controlling the balance of excitatory and 524 
inhibitory inputs on post-synaptic neurons (Lin et al., 2008; Bloodgood et al., 2013; Spiegel et al., 525 
2014). We measured the amount of two neuromediators, GABA (released at inhibitory 526 
synapses) and glutamate (released at excitatory synapses) in the medium and in the cells of 527 
primary neurons at DIV7 (Fig. 5A-B). The concentration of GABA was increased by 83% in the 528 
medium of APP-/- neurons (Fig. 5A). No significant change in glutamate concentration (cell or 529 
medium) was observed in APP-/- neuronal cultures when compared to APP+/+ (Fig. 5B). In line 530 
with this observation, we measured only very subtle changes in glutamate responses in APP-/- 531 
neurons when compared to APP+/+ (Extended Data Fig. 5-1), pointing toward a specific 532 
impairment in GABA-dependent signaling in the absence of APP. GABA is synthetized in 533 
inhibitory neurons by the glutamate decarboxylase enzymes (GAD65 and GAD67). GAD65 is 534 
active at nerve terminals and synapses. We observed that GAD65 signal is increased in APP-/- 535 
neurons when compared to APP+/+ (Fig. 5C). This is not caused by an increase in the relative 536 
number of GAD65 positive neurons in APP-/- cultures (Extended Data Fig. 5-2), but likely to an 537 
increase in GAD65 expression in GABAergic neurons. To further address the effect of APP 538 
deficiency on GABAergic synaptic markers, we first quantified the expression of GABARα1, a 539 
GABAA receptor subunit predominantly expressed during neuronal development. We found a 540 
slight but significant decrease in GABARα1 in APP-/- neurons (Fig. 5D). To evaluate if the 541 
activity of GABA receptors was defective in physiological conditions, cortical neurons at DIV7 542 
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were voltage-clamped at -60mV. To prevent neuronal activity, experiments were performed in the 543 
presence of 1 μM TTX, 10 μM CNQX, 20 μM D-AP5 and 100 nM CGP55845 to inhibit Na+ 544 
voltage-dependent channels, AMPA, NMDA and GABAB receptors, respectively. Current-voltage 545 
(IV) curves were generated by evoking the current with a voltage ramp stimulus from -90mV to 546 
+60mV, and the response to 100 μM was studied (Fig. 5E). Whole cell currents evoked at -50mV 547 
or +50mV by 100μM GABA were similar in APP+/+ as in APP-/- neurons (Fig. 5F). This patch-548 
clamp investigation did thus not reveal any functional decrease in GABAA receptors, suggesting 549 
that the minor decrease in expression of GABARα1 subunit was compensated. 550 
Finally, we evaluated the impairment in GABAergic markers in the brain of APP-/- mice. We 551 
quantified the expression of GAD65 and GABARα1 in cortices and hippocampi of 3-month-old 552 
mice. A significant increase in GAD65 expression was observed both in cortex (Figure 6A) and 553 
in hippocampus (Figure 6B) of APP-/- mice, and decreased GABARα1 levels were measured 554 
especially in the hippocampus. We analyzed CA3-to-CA1 synapse plasticity by extracellular 555 
recordings on hippocampal slices from adult APP+/+ and APP-/- mice. Schaffer collaterals (SC) 556 
were stimulated and fEPSP were recorded in the stratum radiatum of CA1 region. We observed 557 
that the relationship between the stimulus intensity and the fEPSP slope was similar in slices 558 
from both genotypes (Extended Data Fig. 6-1A). To investigate LTP, we stimulated the SC 559 
pathway with a theta- burst stimulation (TBS) consisting of four bursts of five pulses (given at 560 
100 Hz) separated by 200 ms. In slices from APP+/+ animals, TBS induced a large increase of 561 
the fEPSP response size that decayed over the first 20 minutes to a plateau level persisting up 562 
to the end of the experiment. In APP-/- mice, LTP was significantly reduced (Fig. 6C). Typically, 563 
60 min after the TBS, LTP was reduced by half. The response to TBS itself was actually 564 
modified: the second, third and fourth bursts of stimulation were globally decreased in APP-/- 565 
compared to APP+/+, and within each of the four bursts of 5 pulses, the responses to the third, 566 
fourth and fifth stimuli decreased more in slices form APP-/- mice than in APP+/+ (Fig. 6D).  567 
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 569 
Silencing NPAS4 mimics APP deficiency in neurons 570 
We used the CRISPR-Cas9 approach in order to directly silence NPAS4 expression in neurons 571 
and analyze whether NPAS4 deficiency could recapitulate a major trait observed in APP-/- 572 
neurons, i.e. the upregulation of GABA release and modification of GABAergic markers. The 573 
efficiency of CRISPR-Cas9 editing is hard to evaluate by quantifying the mRNA levels of the 574 
target gene, since decrease in mRNA could only occur if nucleotide insertions by non-575 
homologous end-joining results in nonsense-mediated RNA decay. Commercially available 576 
antibodies poorly detect NPAS4 in basal conditions, but we could still observe that NPAS4 577 
protein was diminished upon silencing (CRISPR-NPAS4 condition, Fig. 7A). We further decided 578 
to check the down-regulation of NPAS4 gene expression by measuring NPAS4 protein upon 579 
depolarization by KCl (Lin et al., 2008). In that condition, we found that CRISPR-Cas9-induced 580 
silencing resulted in a decrease in NPAS4 by approximately 50% (Fig. 7A). This is comparable 581 
to the decrease in NPAS4 mRNAs measured in APP-/- neurons at DIV7 (Fig. 1D). As for 582 
CRISPR-Cas9 lentiviral vectors targeting APP, we did not observe toxic effects related to viral 583 
transduction of primary neurons (See Extended Data Fig. 3-1C). Strikingly, like APP-deficient 584 
primary neurons (Fig. 5C) or brains of APP-/- mice (Fig.6), NPAS4-deficient neurons showed an 585 
increase in GAD65 staining (Fig. 7B-C) and GAD65 protein expression (Fig. 7D). Accordingly, a 586 
2.5-fold increase in GABA concentration was measured in the medium of primary neurons 587 
infected with CRISPR-Cas9 NPAS4 lentiviruses (Fig. 7C). The expression of GABA receptor 588 
subunit alpha 1 (GABARa1) was decreased after NPAS4 knockdown (Fig.7D), to the same 589 
extent as the decrease observed in in APP-/- primary neurons (Fig. 5D). 590 
  591 
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Discussion  592 
One major function of APP is to control synaptic formation, transmission and plasticity (Muller et 593 
al., 2017). We showed here that APP deficiency in cortical neurons impairs the balance between 594 
excitatory and inhibitory synaptic markers, and increases GABAergic transmission. This process 595 
relies on the activity-dependent transcription factor NPAS4. We initially identified the NPAS4 IEG 596 
as downstream APP target by a non-biased transcriptome analysis. The APP-dependent 597 
transcription of NPAS4 involves its extracellular domain (sAPPα) and is activated by AICD. APP 598 
appears thus to exert a fine tuning of inhibitory synapses in neuronal network. Its absence 599 
enhances, through the downregulation of NPAS4, the production and the release of GABA. 600 
APP-dependent expression of NPAS4 in differentiated neurons 601 
The transcriptome analysis of APP+/+ vs. APP-/- neurons at embryonic day 18 (E18-DIV0) and 602 
at different stages of primary cortical neuron differentiation (DIV3-DIV7) indicated that the 603 
transcriptional changes in the absence of APP were moderate. This unexpected result is in line 604 
with a comparative transcriptome study of APP family members in the adult mouse cortex (Aydin 605 
et al., 2011). Subtle effects of APP deficiency on the transcriptome could be due to functional 606 
redundancies with other APLPs that display similar functions and signaling properties (Shariati 607 
and De Strooper, 2013). We did not measure any changes in APLP1 and APLP2 expression in 608 
our APP-/- models, in agreement with studies done on total brain extracts (Zheng et al., 1995) or 609 
in primary cortical neurons (White et al., 1998). Transcriptional modifications we measured are 610 
thus related to the absence of the APP protein per se. APP-dependent transcriptional 611 
regulations likely act by fine-tuning the expression of classes of gene involved in neuronal 612 
pathways rather than robustly regulating single target genes. We found that the expression of 613 
the NPAS4 ITF is downregulated in the absence of APP. This particularly at DIV7, when primary 614 
neurons start to form a functional network. NPAS4 downregulation was observed it in APP-/- 615 
primary neurons and upon acute APP knockdown by a CRISPR-Cas9 approach, establishing a 616 
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link between APP and NPAS4 transcription. Regarding the possible molecular mechanisms 617 
involved here in APP-dependent gene transcription, we found that NPAS4 expression is 618 
activated in neurons by AICD expression. It correlates with the fact that DIV7 corresponds to the 619 
differentiation stage where AICD is peaking in primary cortical neurons. (Kimberly et al., 2005). 620 
However, previous studies showed the secreted ectodomain (sAPPα) is sufficient to rescue 621 
functional defects in APP KO mice (Ring et al., 2007; Weyer et al., 2014). We found that 622 
treatment of APP+/+ neurons (and not APP-/- neurons) with sAPPα significantly increased 623 
NPAS4 mRNAs. This observation indicates that (i) the effects of sAPPα require the presence of 624 
endogenous APP (ii) homophilic ectodomain interactions are likely to be involved. Soluble APP 625 
was suggested to promote its physiological effects by interaction with APP holoprotein (Milosch 626 
et al., 2014; Deyts et al., 2016). It is tempting to suggest here that interaction of soluble APP with 627 
APP holoprotein present at the cell surface could induce the release of transcriptionally active 628 
AICD, but this hypothesis awaits further experimental evidence. 629 
Alteration of GABA release and GABA markers in APP deficient neurons 630 
In the absence of APP, we observed an increase in neuronal outgrowth and GAD65 signal, as 631 
well as increased GABA release in the medium of primary neurons. The increase in GAD65 632 
signal was related to an increased signal in GAD65-positive neurons, not to an increased 633 
number of GAD65 neurons in our primary cultures. It would be useful to further investigate as to 634 
whether an increase in the numbers and functionality of GABAergic neurons occurs in the brain 635 
of APP -/- mice. To note, APP was reported to control neurogenesis in adult mice brain (Wang et 636 
al., 2014), as process that could account for the modification of neuronal subtypes observed in 637 
the absence of APP.  638 
The increase-in GAD65 we observed was in line with increased levels of GABA in the culture 639 
medium. In vivo studies evidenced increased GABA levels in the brain of APP-/- mice (Lee et al., 640 
2010). However, this elevation of GABA markers was concomitant to a down-regulation in the 641 
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GABARα1 receptor subunit. Recent study also reported that GABARα1 is particularly decreased 642 
in hippocampus of APP-/- mice (Chen et al., 2017), in line with our in vivo experiments. Still, 643 
patch-clamp experiments did not reveal any decrease in GABAA receptors functionality, 644 
indicating that compensation may occur to circumvent the decrease in a GABAA receptor 645 
subunit, and that GABAergic transmission per se is not significantly altered. 646 
On the other hand, our results show that LTP is reduced in brain slices from APP-/- mice. This is 647 
in agreement with previous studies showing that the LTP induced by one TBS is reduced in 648 
APP-/- at the SC-CA1 synapses (Dawson et al., 1999;Seabrook et al., 1999;Ring et al., 2007) 649 
but not at the perforant path-granule cell (DG) synapse that we did not study here (Jedlicka et 650 
al., 2012), Such inhibition was however not observed by other investigators (Wang et al., 2017), 651 
possibly because they used a stronger stimulation protocol (3 TBS). Interestingly, the analysis of 652 
the responses to the TBS itself is consistent with increased GABAergic release in APP-/- mice. 653 
How could APP modulate GABA release? Soluble APP (sAPPα) is known to enhance LTP and it 654 
is sufficient to rescue the decrease of LTP observed in APP-/- mice (Taylor et al., 2008;Ring et 655 
al., 2007). Moreover, very recent studies showed that the sAPPα directly binds the GABAB 656 
receptor subunit 1a (GABABR1a), suppressing synaptic transmission and triggering short-term 657 
facilitation in hippocampal neurons (Rice et al., 2019). Such an effect of sAPPα could explain the 658 
smaller response observed in brain slices from APP-/- mice compared to APP+/+. Indeed, in 659 
APP-/- slices, a larger release of GABA would occur in the absence of GABABR1a stimulation by 660 
sAPPα, therefore reducing the disinhibitory process observed between the first and the second 661 
burst of stimuli of the TBS (Larson and Munkacsy, 2015). This supports that APP synaptic 662 
function and APP-dependent synaptic transmission are mediated by the soluble sAPPα 663 
fragment. We suggest that the NPAS4 IEG is sensing the APP-dependent modulations of 664 
synaptic transmission. Our results also indicate that NPAS4 knockdown mimics APP deficiency 665 
on GAD65 levels and GABA measurements. The finding that APP functions in neuronal network 666 
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might be mediated by NPAS4 is relevant to several evidences about the reported role of NPAS4 667 
in neuronal network activity. NPAS4 possesses unique features among the IEGs (Sun and Lin, 668 
2016): (i) it is only expressed in neurons; (ii) it is activated selectively by neuronal activity; (iii) it 669 
has been shown to shape glutamatergic and GABAergic synaptic inputs. NPAS4 is implicated in 670 
a transcriptional program that regulates neuronal firing responses to excitatory transmission by 671 
enhancing inhibition (Lin et al., 2008), and is critical to keep neuronal firing in response to stimuli 672 
within normal levels (Spiegel et al., 2014). This exciting new field of investigation connecting 673 
APP function to ITFs sensing neuronal activity awaits further investigation.  674 
Possible relevance to the AD pathophysiology 675 
APP plays a central role in the onset and progression of the amyloid pathology found in AD. 676 
Apart from producing Aβ, the precise contribution of the APP protein to the pathology is poorly 677 
understood. The impairment of APP function, either caused by Familial AD (FAD) mutations or 678 
upon neuronal ageing, may contribute to neuronal dysfunctions occurring in the disease. In the 679 
mammalian brain, APP modulates dendritic complexity, synaptic functions and synaptic plasticity 680 
(Muller et al., 2017). A reduction in dendritic length and branching as well as in total spine 681 
density was reported in old APP-deficient mice (Lee et al., 2010; Tyan et al., 2012). Aging is an 682 
important parameter related to APP functions in the brain. The phenotype related to APP 683 
deletion in the central nervous system (CNS) is age-dependent (Priller et al., 2006). Upon aging, 684 
impairments in learning and memory associated with deficits in LTP are observed in APP-685 
deficient mice as shown here and in previous studies (Ring et al., 2007). Interestingly, the 686 
decline in memory performance and reduction in LTP observed in old mice and APP transgenic 687 
mice are mediated by the ionotropic GABAA receptor (Yoshiike et al., 2008). This imbalance in 688 
neuronal excitatory/inhibitory transmission was also observed in the temporal cortex of AD 689 
patients, where significantly lower levels of GABA and glutamate were measured (Gueli and 690 
Taibi, 2013). These observations unambiguously indicate that changes in neurotransmission 691 
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occur in AD (and even in ageing brain) and point toward alteration of the inhibitory GABAergic 692 
transmission. Important points must be kept in mind here. First, GABAergic transmission shifts 693 
from excitatory to inhibitory during development (Ben-Ari, 2002), so the consequence of altered 694 
GABAergic transmission can be fully understood only in adult brain. Then, the molecular 695 
mechanisms underlying changes in inhibitory transmission in AD are complex. The GABAergic 696 
molecular actors are differentially affected by ageing (Vela et al., 2003) or in AD mice models 697 
(Yoshiike et al., 2008). Decrease in GABARα1 has been reported in ageing rodent brain and in 698 
the hippocampus of aged brains with AD (Mizukami et al., 1998), but this could be functionally 699 
compensated as shown herein. Our findings should further be addressed in AD mice models 700 
(expressing APP mutations) to complete the results obtained here in a loss-of-function model 701 
(APPKO). However, the hypothesis of an overall impairment of GABAergic transmission in AD is 702 
also supported by the increased risk for unprovoked seizures observed in individuals with AD 703 
compared to non-demented individuals of the same age (Friedman et al., 2012). 704 
Finally, NPAS4 expression was found to decrease along with AD progression, particularly at 705 
Braak NFT stages (I-II) corresponding to lesions developed in transentorhinal/entorhinal cortex 706 
(Miyashita et al., 2014). We believe that our main observation, namely that APP deficiency in 707 
neurons is integrated by the activity-dependent NPAS4 IEG and affects the balance of inhibitory 708 
and excitatory neuronal inputs, provides new insight to understand the role of APP in synaptic 709 
activity, but also a mechanistic frame to further explore the impairments of network activity in 710 
AD. 711 
  712 
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Figure Legends 713 
Figure 1: APP-dependent expression of NPAS4 in young differentiating neuronal culture 714 
Summary of transcriptome analysis performed with the GeneChip® Mouse Transcriptome Array 715 
1.0 (Affymetrix). The characterization of the model and the experimental workflow are described 716 
in Extended Data Fig. 1-1. Data were processed in triplicate (N=3) for each experimental time 717 
point (E18; DIV3; DIV7). Non-coding transcripts and alternative splicing products were detected 718 
by these arrays, but only transcripts of coding transcripts have been considered here. For all the 719 
transcripts, adjusted p-value > 0.05 except for APP (internal control, p-value < 0.05). A) Number 720 
of up-and down-regulated coding transcript in APP-/- vs. APP+/+ primary neurons at E18, DIV3 721 
and DIV7. Linear fold changes have been set at 1.25, 1.5 and 2. B) KEGG pathway analysis 722 
(http://www.genome.jp/kegg/pathway.html) at E18, DIV3, DIV7 (APP-/- vs. APP+/+) to identify 723 
networks molecular pathways (or interaction networks) in which differentially expressed genes 724 
are clustered. The five most modified pathways are displayed for each time point, with the 725 
number of genes potentially up-or down-regulated. C) Immediate Early Genes (IEGs) expression 726 
in APP-/- vs. APP+/+ primary neurons at DIV7 and their respective fold change (APP-/- vs 727 
APP+/+) in microarray analysis at DIV7. D) Neuronal PAS 4 domain (NPAS4) mRNA level was 728 
measured by qPCR at E18, DIV3 and DIV7 (n=6, N=3). Results (mean ± SEM) are expressed as 729 
percentage of controls (APP+/+). n.s.= non-significant, *p=0.0242, Student’s t-test. mRNA levels 730 
of two other IEGs (Egr1 and Egr3) were measured in the same conditions (Extended Data Fig. 731 
1-2). 732 
Figure 2: APP metabolites regulate NPAS4 expression 733 
A) Schematic representation of APP, its fragments, the AICD-HA construct along with and the 734 
localization of the epitopes recognized by the different antibodies used. Western blotting 735 
analysis of AICD-HA expression after 3 days of lentiviral infection in cells with control or AICD-736 
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HA expressing vectors. Total cell lysate was analyzed with anti-HA antibody. B) Quantification 737 
by qPCR of NPAS4 mRNA in neurons APP-/- at DIV7 infected with lentiviral vector expressing 738 
AICD-HA (n=6, N=3). Results are expressed as percentage of control (Ct) (mean± s.e.m). *p.= 739 
0.0291, Student-t test. C) Medium of sAPPα treated APP+/+ or APP-/- neurons was subjected to 740 
Western blotting analysis using anti-human APP antibody (clone W0-2) to detect the exogenous 741 
human sAPPα (h sAPPα) and an anti-mouse APP antibody (clone 22C11) to detect both 742 
endogenous and exogenous sAPPα (h+m sAPPα). Medium was collected after 16 h of 743 
treatment. D) Quantification by qPCR of NPAS4 mRNA level in APP+/+ (n=8, N=4) or in APP-/- 744 
neurons at DIV7 treated with 20 nM sAPPα for 16 h (n=6, N=3). Results are expressed as 745 
percentage of control (Ct) (mean ± s.e.m.). **p=0.0055, n.s.= non-significant, Student-t test. 746 
Given that primary cultures of cortical neurons at DIV 7 also contain astrocytes, the astrocytic 747 
pattern of NPAS4 expression is described in Extended Data Fig. 2-1. 748 
Figure 3: Decreased NPAS4 expression in APP-silenced primary neurons 749 
APP was knockdown by CRISPR-Cas9 approach in primary neurons cultures. The infectivity 750 
and toxicity of lentiviral CRISPR-Cas9 vectors are detailed in Extended Data Fig. 3-1. A) APP 751 
expression characterization in neurons by immunostaining. Cortical neurons were infected at 752 
DIV1 with lentiviruses expressing sgRNAs (Oligo2, Oligo17) or not (Ct). All lentiviruses harbor a 753 
GFP expression cassette. Cultures were immunostained for MAP2 (red), APP (blue) and DAPI 754 
(light blue) at DIV7. Arrowheads indicate the position of GFP-positive (infected) neurons in each 755 
condition. Scale bar: 100μm. B) Quantification of APP signal in GFP-positive neurons by Image-756 
J. At least 33 neurons were quantified in two independent experiments for each condition (n=33 757 
N=2). Results (mean ± SEM) are given as percentage of control (Ct). ###p<0,001 (Ct vs Oligo 2) 758 
***p<0.001 (Ct vs Oligo17); Kruskal-Wallis test and Dunn’s multiple comparison test. C) Upper 759 
panel. Representative Western blots showing APP, APLP1, APLP2 and GAPDH protein levels in 760 
cortical neurons at DIV7 infected in the same conditions as in Fig 1A. NI = non-infected. Lower 761 
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panel. Quantification of APP expression in total cell lysates measured by Western blotting. 762 
Results (mean ± SEM) are given as percentage of control (Ct). ***p<0,001 (Ct vs Oligo17), 763 
###p<0.001 (Ct vs Oligo 2), ANOVA and Bonferroni’s multiple comparison test (n=6, N=3). D) 764 
Sorting of GFP-expressing neurons (FACS). Scatter plots (FSC vs. SSC, left panels) of non-765 
infected and GFP-expressing cells are shown. Dot plots (TOPRO-3, far red vs. GFP, right 766 
panels) were used to gate (green rectangle) GFP-positive/TOPRO-3 negative cells. RNA was 767 
extracted from these cells and NPAS4 mRNA level was quantified by qPCR. Results were 768 
obtained from pooled samples (4 wells of 4 cm2 each) for each condition (Ct, Oligo2 and 769 
Oligo17). Quantification was carried out on 2 independent experiments (N=2). Results (mean ± 770 
SEM) are expressed as percentage of Ct. 771 
Figure 4: Altered neurites arborization of APP deficient neurons during in vitro maturation 772 
A) Cortical APP+/+ or APP-/- were stained against the neuron-specific marker MAP2 and the 773 
nuclear dye DAPI at different stages of maturation (DIV1-2-3 and DIV7). Scale bar: 400μm. B) 774 
Quantification by ImageJ of MAP2 signal area normalized to the number of neurons at DIV1, 2, 3 775 
and 7. Quantifications were from 3 fields of at least 6 coverslips from APP+/+ and APP-/- 776 
neurons, in three independent experiments (N=3). Results (mean ± SEM) are expressed as 777 
percentage of control (APP+/+). *p=0.0293, Mann-Whitney test.  778 
Figure 5: GABAergic markers and GABAergic transmission in APP knockout neurons 779 
A) Quantification of γ-amino butyric acid (GABA) in culture medium and cell extracts of APP+/+ 780 
and APP-/- primary neurons at DIV7. Results (mean ± SEM) are expressed as percentage of 781 
APP+/+ (n=20, N=3). **p=0.0024, n.s.= non-significant, Student-t test. B) Quantification of 782 
glutamate in culture medium and cell extracts of APP+/+ and APP-/- neurons at DIV7. Results 783 
(mean ± SEM) are expressed as percentage of APP+/+ (n=16, N=3). n.s.= non-significant, 784 
Student-t test. Glutamate responses measured in APP-/- neurons are shown in Extended Data 785 
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Fig. 5-1. C) Cortical APP+/+ and APP-/- neurons at DIV7 were immunostained for the neuron-786 
specific marker MAP2 and glutamate decarboxylase 65 (GAD65). Arrows indicate MAP2/GAD65 787 
positive neurons, shown at higher magnification (insets). The expression profile of the GAD65 788 
GABAergic marker in APP+/+ and APP-/- neurons is detailed in Extended Data Fig. 5-2. GAD65 789 
signal (5 fields per coverslip) was normalized for quantification to the number of cells in the area 790 
(histogram on the right). At least 2 coverslips were quantified for each group (APP+/+ and APP-791 
/-) in two independent experiments (N=2). Results (mean ± SEM) are given as percentage of 792 
control (APP+/+). Scale bar: 200μm. *p=0.0220, Mann-Whitney test. D) Neurons harvested at 793 
DIV7 and cell extracts analyzed by Western blotting for GABARα1 and GADPH expression. 794 
Quantification of GABARα1 was normalized to GAPDH expression. Results (mean ± SEM) are 795 
expressed as percentage of Ct (n=5, N=2). *p=0.0197, Student’s t-test. E) Representative I-V 796 
traces (from −90 to +60 mV repeated every 0.1 s) through APP+/+ (A) and APP-/- (B) neurons, 797 
in the presence 100 μM GABA (red traces). F) Pooled data of whole-cell current (at +50 and -50 798 
mV) evoked by 100 mM GABA, through APP WT and KO neurons. Each column represents 799 
mean ± SEM of n=8 cells. 800 
Figure 6: GABAergic markers and LTP in adult mice  801 
A) Left panel: Western blot analysis of GAD65, GABARα1 and GAPDH expression in cortex of 3 802 
month old APP+/+ and APP-/- mice (N=5). Right panel: Quantification of GAD65 and GABARα1 803 
were normalized to GAPDH expression. Results (mean ± SEM) are expressed as percentage of 804 
APP+/+ (N=5). *p=0.0166, Student’s t-test. B) Left panel Western blot analysis of GAD65, 805 
GABARα1 and GAPDH expression in hippocampus of 3 month old APP+/+ and APP-/- mice 806 
(N=5). Right panel Quantification of GAD65 and GABARα1 were normalized to GAPDH 807 
expression. Results (mean ± SEM) are expressed as percentage of APP+/+ (N=5). *p=0.0404, 808 
Student’s t-test. LTP was measured in hippocampal SC-CA1 pathway from APP+/+ (n=9) and 809 
APP-/- mice (n=8). The input-output relationship between fEPSP measured in CA1 stratum 810 
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radiatum and the intensity of SC stimulation is depicted in Extended Data Fig. 6-1. C) fEPSP 811 
slopes measured during TBS (p<0.05; two-way repeated measurements ANOVA, Bonferroni). 812 
D) fEPSP slopes measured before and after TBS. Results expressed in proportion of the 813 
baseline response (100%). (p<0.05; two way repeated measurements ANOVA, Bonferroni). 814 
Figure 7: NPAS4 silencing by CRISPR-Cas9 mimics cell phenotype observed in APP 815 
deficient neurons. 816 
Changes on inhibitory (GABA) synapses was analyzed after NPAS4 silencing A) Left panel. 817 
Cortical neurons infected with CRISPR-Cas9 lentivirus targeting NPAS4 gene (CRISPR-NPAS4) 818 
show reduced NPAS4 levels as measured by Western blotting (high exposure). Same 819 
experiments were carried out after membrane depolarization with 50mM potassium chloride 820 
(KCl). NPAS4 accumulations was detectable by Western blotting at low exposure. Viruses 821 
without sgRNA were used as controls (Ct). Right panel. Quantification of NPAS4 protein level 822 
after 2, 3 and 4h of KCl depolarization. Results (mean ± SEM) are expressed as percentage of 823 
non-treated controls Ct (N=2). ***p<0.0001 Student’s t-test. B) Cortical neurons infected with 824 
CRISPR-NPAS4 lentiviruses at DIV1 were immunostained against MAP2 and glutamate 825 
decarboxylase 65 (GAD65) at DIV7. Quantification of GAD65 signal was normalized to the 826 
number of cells (5 fields per coverslip, 2 coverslips for each genotype in two independent 827 
experiments, (N=2). Results (mean ± SEM) are given as percentage of control (Ct). Scale bar: 828 
200μm. **p=0.0024. Mann-Whitney test. C) Quantification of γ-amino butyric acid (GABA) in 829 
culture medium at DIV7of infected control neurons (Ct) and CRISPR-NPAS4 infected neurons. 830 
Results (mean ± SEM) are expressed as percentage of Ct (n=5, N=2). *p=0.0146, Student-t test. 831 
D) Neurons harvested at DIV7 and cell extracts analyzed by Western blotting for GABARα1, 832 
GAD65 and GADPH expression. Quantification of GABARα1 and GAD65 were normalized to 833 
GAPDH expression. Results (mean ± SEM) are expressed as percentage of Ct (n=8, N=3). 834 
*p=0.049, #p=0.0247, Student’s t-test. 835 
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 836 
Extended Data Figure Legends 837 
Figure 1-1: Experimental workflow and model characterization 838 
A) Experimental design used for the study (E18); neurons were cultured and experiments were 839 
mainly carried out after 3 and 7 days in vitro (DIV3 and DIV7). Transcriptome analysis was 840 
performed on embryonic cortex (E18) and at DIV3 or DIV7. B) APP, APLP1 and APLP2 841 
expressions were analyzed by Western blotting at the indicated days of culture in APP+/+ 842 
neurons. C) Quantification of APP, APLP1 and APLP2 protein expression over time in APP+/+ 843 
neurons. Accumulation is represented as fold change over the signal measured at day 0. 844 
Quantification was performed from one neuronal culture D) APLP1 and APLP2 expressions are 845 
not modified in cortical tissue at E18 and primary neuron cultures at DIV3 and DIV 7 in absence 846 
of APP. Expression of APP, APLP1, APLP2 was analyzed by Western blotting of cells lysates 847 
from APP+/+ and APP-/- primary neuron cultures. E) Samples from primary cultures at DIV7 848 
(APP+/+, APP+/- and APP-/- neurons) were probed (Western blotting) with an antibody directed 849 
against APP C-terminus for APP C-terminal fragments (CTFs) and AICD. Low and high 850 
exposures of a typical blot are shown. Arrows indicate the expected position of APP holoprotein, 851 
APP CTFs and AICD. 852 
Figure 1-2: Expression of Egr1 and Egr3 is not modified in APP-/- neurons 853 
Egr1 and Egr3 expressions were evaluated in APP+/+ vs. APP-/- primary neurons at DIV7. A) 854 
Egr1 mRNA and B) Egr3 mRNA levels was measured by qPCR (n=6, N=3) at DIV7. Results 855 
(mean ± SEM) are given as percentage of controls (APP+/+) n.s= non-significant, Student’s t-856 
test. 857 
 858 
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Figure 2-1: Astrocytes in primary neuron culture and their implication in Npas4 859 
expression.  860 
A) Primary culture of cortical neurons at DIV7. Cultures were immunostained with the neuron 861 
specific protein MAP2 (green), the glial specific protein GFAP (red) and the DAPI (light blue). 862 
Scale bar = 400μm. B) Quantification of neurons (MAP2+) and astrocytes (GFAP+) in the 863 
primary cortical culture. At least five fields per coverslip were analyzed for APP+/+ and APP-/- 864 
cultures in two independent experiments (n≥5, N=2). Results are expressed as the ratio of 865 
MAP2+ (neurons) and GFAP+ (astrocytes) (mean ± s.e.m). n.s= non-significant, Mann-Whitney 866 
test. C) Western blotting analysis of NPAS4 induction in neurons and astrocytes after 867 
depolarization with 50mM potassium chloride (KCl) for 2 hours.  868 
Figure 3-1: Infectivity and toxicity of lentiviral CRISPR-Cas9 vectors 869 
A) Cortical neurons were infected at DIV1 with lentiviruses expressing sgRNAs (Oligo2, Oligo17 870 
or CRISPR-NPAS4) or no sgRNA (Ct), SpCas9 and GFP. Cultures were immunostained for 871 
MAP2 (red) and DAPI (light blue) at DIV7. Scale bar = 400μm. B) Quantification of GFP+ 872 
neurons (GFP+/MAP2+) in total neuron population (MAP2+) after lentiviral CRISPR-Cas9 873 
infection with control (Ct), Oligo2, Oligo17 or CRISPR-NPAS4. At least five fields were analyzed 874 
for each lentiviral vector in two independent experiments (n≥5, N=2). Results are expressed as 875 
percentage of GFP+/MAP2+ cells in total MAP2+ cells (mean ± s.e.m). n.s= non-significant, 876 
Kruskal-Wallis test and Dunn’s multiple comparison test. C) Measurement of LDH activity 877 
released after infection (DIV7) of primary neuron with control (Ct), Oligo2, Oligo17 or CRISPR-878 
NPAS4 at DIV7 lentiviral vectors. Background LDH release was determined in non-infected 879 
control cultures (NI). Results were expressed as percentage of total LDH release measured in 880 
non-infected control cultures (NI) in 2 independent experiments (n=12, N=2). 881 
Figure 5-1: Glutamate responses in APP-/- neurons measured by calcium imaging. 882 
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Neuronal activity was measured at DIV7 by calcium imaging. A) Left panel. Different calcium 883 
responses were observed after stimulation with 50 μM glutamate and classified as described by 884 
Prickering and co-workers (Prickering et al. 2008) between neuronal and non-neuronal 885 
responses. To note X-axe graduation correspond to 20 sec. Right panel. The proportion of cells 886 
displaying Type 1, 2 or 3 response was quantified in three independent experiments (n=9, N=3). 887 
n.s.= non-significant. Student-t test. B) Normalized fluorescence trace (mean ± SEM) measured 888 
in APP+/+ and APP-/- neurons upon perfusion for 150 sec with 50 μM glutamate. The area 889 
under curve (AUC) was quantified for 50 neurons per coverslips. A total of 9 coverslips for each 890 
genotype was recorded in three independent experiments (N=3). The graph on the right shows 891 
AUC expressed as percentage of control (APP+/+). *p=0.0106, Student’s t-test. 892 
Figure 5-2: GAD65 positive neurons in primary cortical cultures. 893 
A) Primary culture of cortical neurons after at DIV7. Cultures were immunostained with the 894 
neuron specific protein MAP2 (red), GAD65 (dark blue) and DAPI (light blue). Representative 895 
20x micrographs show GAD65 positive neurons (white arrowhead) and GAD65 negative neuron 896 
(green arrowhead). B) Images (20x objective) were quantified (10 fields per coverslip for each 897 
genotype) in three independent cultures (n=30, N=3). Results (mean ± s.e.m) are expressed as 898 
percentage of GAD65+ MAP2+ cells (GAD65+ neurons) among all MAP2+ cells (neurons). n.s= 899 
non-significant, Mann-Whitney test. Scale bar = 20μm. 900 
Figure 6-1: LTP in hippocampal SC-CA1 pathway in APP-/- mice 901 
Excitatory postsynaptic potentials measured in hippocampal CA1 region of brain slices from 902 
APP+/+ (N=9) and APP-/- mice (N=8). A) The input-output relationship between fEPSP 903 
measured in CA1 stratum radiatum and the intensity of SC stimulation is represented. No 904 
significant difference between APP+/+ and APP-/- was observed.  905 
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